Call Us Sign-Up/Sign-In
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

iCrowdNewswire Oct 26, 2020 10:06 AM ET

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

iCrowd Newswire - Oct 26, 2020

WPD Pharmaceuticals Inc. a clinical-stage pharmaceutical company, is pleased to provide an update on the development of its licensed Berubicin drug candidate in celebration of National Brain Cancer Day on October 24, 2020 in Canada.

WPD is conducting research related to the development of Berubicin, as a novel drug candidate in glioblastoma multiforme (“GBM”) therapy for children and adult patients, as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. The main goal of the project is to implement a multicenter pediatric phase I clinical trial to determine the maximum tolerated dose and also clinical trials in adults, in order to confirm the efficacy of Berubicin. Berubicin is an innovative drug candidate, licensed from CNS Pharmaceuticals, Inc. in certain territories, being studied to determine its effects on brain cancer cells that are resistant to temozolomide, which today is used as the standard chemotherapeutic. The project also provides for preclinical testing to determine the possible use of Berubicin in combination with temozolomide and with other compounds being developed by WPD and by other companies as candidates for anticancer drugs.

Last week, WPD met with Worldwide Clinical Trials, a world-renowned Contract Research Organization engaged to coordinate and supervise the start-up of WPD’s Phase 1 and 2 clinical trials on Berubicin. The discussions indicated that the Berubicin adult trial is expected to commence in February 2021 and the children multicenter pediatric phase I clinical trial later in 2021. About 60% of the program budget is expected to be refunded by a grant already awarded to WPD by The National Center for Research and Development based in Poland under the European Union’s Smart Growth Operational Program.

BIO Europe Digital Conference

WPD is also pleased to announce that the Company has been invited to present at the Bio-Europe Digital conference October 26-29, 2020. BIO Europe is a leading European Pharmaceuticals event with 4,000 executives from over 60 countries. Due to COVID-19, The BIO Europe conference will be virtual this year and attendees will have access to on demand panels on BD&L, Finance, Therapeutic Areas and up-to-the-minute spotlight topics. For more information on the conference, visit:

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.  The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.

On Behalf of the Board

‘Mariusz Olejniczak’

Mariusz Olejniczak
CEO, WDP Pharmaceuticals


Investor Relations
Tel: 604-428-7050


Contact Information:

Mariusz Olejniczak
CEO, WDP Pharmaceuticals

Tags:    Wire, Disclosure Newswire, United States, English